Xelios PharmaResearch is a private drug development company based in Geneva, Switzerland. We focus on the discovery and development of novel treatments for specific skin diseases.

Xelios PharmaResearch has currently one drug candidate in preclinical development. The disease targeted is Molluscum contagiosum, which is caused by Molluscum contagiosum virus, a member of the poxvirus family. Although a large number of treatment modalities are currently used to treat this viral skin infection, none of them has a satisfying efficiency, safety and convenience profile.

The previously published sequence of the whole virus genome has allowed us to identify and exploit virus-specific metabolic sensitivities, and to translate this into our first drug candidate for a topical treatment of Molluscum contagiosum.

The business strategy of Xelios PharmaResearch covers the early stages of drug development, from identification of drugs to obtaining intellectual property rights (IP) and clinical development up to phase II. Upon completion of successful early clinical trials, IP will be sold or outlicensed for further development and commercialization to a strong pharmaceutical partner.